One bead, one chemical compound: use of the selectide process for anticancer drug discovery.
A technology for chemical synthesis and testing of libraries of millions of chemical entities has been developed for rapid molecular and cellular screening for drug leads. Each individual compound in the library is on a separate resin bead. Screening for binding activity can be conducted directly on the beads. Biological activity is assessed in solution phase assay by cleaving a portion of the compound from each bead. The molecular structure of the compound of interest is obtained by automated peptide sequencing from the bead of origin. We have applied this technology to anticancer drug discovery as well as to other pharmaceutical targets. For anticancer drug development, current molecular targets include B-cell lymphoma, the EGF receptor, and the HER2-neu receptor. Solution phase screening with dual cleavable libraries is being used for growth inhibition of human tumor cell lines. Initial in vitro leads have been identified in each of these areas of anticancer drug discovery.
Salmon
S E
SE
Arizona Cancer Center, University of Arizona College of Medicine, Tucson 85724.
Lam
K S
KS
Felder
S
S
Yeoman
H
H
Schlessinger
J
J
Ullrich
A
A
Krchnák
V
V
Lebl
M
M
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D008024:Ligands; D009856:Oncogene Proteins, Viral; D010455:Peptides / Q000138:chemical synthesis; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D008024:Ligands; D009856:Oncogene Proteins, Viral; D010455:Peptides; D020794:Receptor Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases